Bristol-Myers Squibb (BMS)

Photo
01.03.2024 • News

BMS to Invest $400 Million in Expansion of Dublin Site

Bristol Myers Squibb (BMS) wants to invest $400 million for the construction and design of a sterile drug product (SDP) facility at its Cruiserath campus in Dublin, Ireland, significantly expanding manufacturing and laboratory capacity at the site.

Photo
28.12.2023 • News

Bristol Myers Squibb Acquires RayzeBio

Bristol Myers Squibb will acquire RayzeBio for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors.

Photo
23.12.2023 • News

Bristol Myers Squibb Takes Over Karuna Therapeutics

Bristol Myers Squibb (BMS) and Karuna Therapeutics have entered into a definitive merger agreement under which the US drug maker has agreed to acquire the Boston-based biopharmaceutical company for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The transaction was unanimously approved by both the BMS and Karuna Boards of Directors.

Photo
09.10.2023 • News

Bristol-Myers Squibb to Acquire Mirati for up to $5.8 Billion

Bristol-Myers Squibb (BMS) announced that it will acquire Mirati Therapeutics for up to $5.8 billion. BMS is to pay $58.00 per share in cash, for a total equity value of $4.8 billion, diversifying its oncology business and adding drugs it hopes can help offset expected lost revenue from patent expirations later this decade.

Photo
21.03.2022 • News

BMS Sues Astra Zeneca in Cancer Drug Patent Row

Bristol-Myers Squibb (BMS) is suing AstraZeneca Pharmaceuticals, alleging that the Anglo-Swedish drugmaker’ Imfinzi to treat lung and bladder cancer infringes several patents related to its blockbuster Opdivo.

Photo
11.08.2021 • News

WuXi STA Closes Purchase of Swiss BMS plant

WuXi STA, CDMO subsidiary of WuXi AppTec, has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland, from US pharma Bristol Myers Squibb. The Chinese company, which announced the purchase plans earlier this year, said the state-of-the-art facility significantly enhances its European capacity.

Photo
02.06.2021 • News

Bristol Myers Squibb Licenses Agenus Antibody

US drugmaker Bristol Myers Squibb has signed an exclusive license agreement for Agenus’ proprietary bispecific antibody program AGEN1777, that blocks TIGIT and a second undisclosed target.

Photo
29.04.2021 • News

Bristol Myers Squibb Builds Dutch Cell Therapy Site

US drugmaker Bristol Myers Squibb has chosen Leiden in the Netherlands for a new cell therapy manufacturing site in Europe as it continues to expand and develop treatments for patients with aggressive hematological cancers.

Photo
11.02.2021 • News

China’s WuXi Buys Bristol Myers Squibb’s Swiss Plant

China contract development and manufacturing organization (CDMO) WuXi STA has agreed to buy Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland, for an undisclosed sum. The site will be WuXi STA’s first facility in Europe. The transaction is expected to complete during the second quarter, subject to the usual conditions and regulatory approvals.

98 more articles

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.